Literature DB >> 7017068

Antidepressant efficacy of tranylcypromine isomers: a controlled study.

H W Moises, H Beckmann.   

Abstract

The (+)- and (-)-isomers of the monoamine oxidase inhibitor (MAO-I) tranylcypromine (TCP) were administered separately in a double-blind controlled study to 20 depressed patients. The Hamilton Depression Rating Scale, the AMP-system and the Bf-s self-rating questionnaire were used for documentation of psychopathological state and autonomic side effects. Overall there was a statistically significant decrease in the Hamilton depression scores (p less than 0.01 for the (+)-isomer, but not for the (-)-isomer group, whereas self-rating scores did not show a significant decrease in either group. Autonomic side effects were more pronounced (p less than 0.05) in the (+)-isomer group. As platelet MAO was significantly stronger (p less than 0.001) inhibited in the (+)-TCP group as compared with the (-)-TCP group, it is suggested that MAO inhibition rather than uptake blockade is the biochemical mechanism responsible for both the antidepressant activity and the autonomic side effects due to TCP medication.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7017068     DOI: 10.1007/bf01249140

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  8 in total

1.  A twin study on three enzymes (DBH, COMT, MAO) of catecholamine metabolism. Correlations with MMPI.

Authors:  H Winter; M Herschel; P Propping; W Friedl; F Vogel
Journal:  Psychopharmacology (Berl)       Date:  1978-04-14       Impact factor: 4.530

2.  The tranylcypromine isomers: a controlled clinical trial.

Authors:  J I Escobar; B C Schiele; R Zimmermann
Journal:  Am J Psychiatry       Date:  1974-09       Impact factor: 18.112

Review 3.  Multiple forms of monoamine oxidase: functional significance.

Authors:  M Sandler; M B Youdim
Journal:  Pharmacol Rev       Date:  1972-06       Impact factor: 25.468

4.  Steric requirements for catecholamine uptake by rat brain synaptosomes: studies with rigid analogs of amphetamine.

Authors:  A S Horn; S H Snyder
Journal:  J Pharmacol Exp Ther       Date:  1972-03       Impact factor: 4.030

5.  Relationship between the action of monoamine oxidase inhibitors on the noradrenaline uptake system and their antidepressant efficacy.

Authors:  E D Hendley; S H Snyder
Journal:  Nature       Date:  1968-12-28       Impact factor: 49.962

6.  Effects of single doses of tranylcypromine on platelet MAO and amine uptake in normal subjects.

Authors:  V Gentil; B Alevizos; M Lader
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

7.  Diagnostic criteria for use in psychiatric research.

Authors:  J P Feighner; E Robins; S B Guze; R A Woodruff; G Winokur; R Munoz
Journal:  Arch Gen Psychiatry       Date:  1972-01

8.  The effects of tranylcypromine isomers on norepinephrine-H3 metabolism in rat brain.

Authors:  T G Reigle; P J Orsulak; J Avni; P A Platz; J J Schildkraut
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

  8 in total
  4 in total

1.  The complete chloroplast genome sequence of Rubus hirsutus Thunb. and a comparative analysis within Rubus species.

Authors:  Qirui Wang; Ziru Huang; Chenshu Gao; Yuqing Ge; Rubin Cheng
Journal:  Genetica       Date:  2021-09-21       Impact factor: 1.082

2.  The potential therapeutic role of the enantiomers and metabolites of mianserin.

Authors:  R M Pinder; A M Van Delft
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

3.  Hydrazine and amphetamine binding to amine oxidases: old drugs with new prospects.

Authors:  P Knowles; C Kurtis; J Murray; C Saysell; W Tambyrajah; C Wilmot; M McPherson; S Phillips; D Dooley; D Brown; M Rogers; M Mure
Journal:  J Neural Transm (Vienna)       Date:  2007-04-04       Impact factor: 3.575

4.  Tranylcypromine isomers and Parkinson's disease: new aspects of an old drug.

Authors:  G P Reynolds; P Riederer; M Sandler
Journal:  J R Soc Med       Date:  1981-09       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.